Compare BioNano Genomics Inc (BNGO) vs Cigna Corp (CI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNano Genomics Inc vs Cigna Corp — how do they compare? BioNano Genomics Inc trades at $1.2 (market cap $13.66M), while Cigna Corp trades at $277.34 (market cap $73.56B). The key difference: Cigna Corp is far larger — about 5385.1× BioNano Genomics Inc's market cap, and Cigna Corp pays a 2.24% dividend while BioNano Genomics Inc pays none. Which is the better fit depends on your goals.
| BNGO | CI | |
|---|---|---|
Market Cap | $13.66M | $73.56B |
Sector | Health | Health |
52-Week High | $4.92 | $311.00 |
52-Week Low | $1.06 | $244.41 |
Enterprise Value | $16.26M | $98.27B |
Dividend Yield | — | 2.24% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BNGO trades at $1.19, up 2.59% today, with bullish technical signals from moving averages. The company shows improving financials with revenue stabilizing around $29M annually and narrowing losses, though it remains unprofitable. Recent earnings have consistently beaten expectations, and analyst sentiment is positive with 57% buy ratings. Key developments include debt retirement and scientific publications highlighting optical genome mapping adoption.
The outlook is cautiously optimistic given improving fundamentals and positive analyst coverage, but significant risks remain due to persistent losses and negative cash flow. Investment opportunity lies in the company's technology adoption growth, while primary risks include profitability challenges and competitive pressures in the genomics space.
Cigna (CI) trades at $275.4, down 1.08% today, with technical indicators signaling a bearish short-term trend. The stock shows strong fundamentals, including a low P/E of 11.51 and consistent earnings beats, with Q2 2026 EPS of $7.78 exceeding expectations. Recent news highlights raised 2026 EPS guidance to at least $30.45, driven by growth in health services and insurance segments.
The outlook is positive, supported by analyst consensus with a $338.90 price target and 73.68% buy ratings. Key risks include competitive pressures and regulatory changes in healthcare. The valuation gap presents an opportunity, but investors should monitor medical cost trends and execution of growth targets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About BioNano Genomics Inc
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →About Cigna Corp
Cigna primarily provides pharmacy benefit management and health insurance services. Its PBM services were greatly expanded by its 2018 merger with Express Scripts and are mostly sold to health insurance plans and employers. Its largest PBM contract is the Department of Defense. In health insurance and other benefits, Cigna mostly serves employers through self-funding arrangements, but it also operates in government programs, such as Medicare Advantage. The company operates mostly in the U.S. with 15 million medical members covered as of the end of 2020, but its services extend internationally, covering another 2 million people.
Read more on CI →
